Global Short Bowel Syndrome Market Research Report (2021 to 2026) – by Drug Class and Region – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Short Bowel Syndrome Market Research Report by Drug Class (GLP-2, Glutamine, and Growth Hormone), by Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) – Global Forecast to 2026 – Cumulative Impact of COVID-19” report has been added to ResearchAndMarkets.com’s offering.

The Global Short Bowel Syndrome Market size was estimated at USD 864.06 Million in 2020 and expected to reach USD 1,026.86 Million in 2021, at a Compound Annual Growth Rate (CAGR) 19.18% to reach USD 2,476.11 Million by 2026.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Short Bowel Syndrome Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Short Bowel Syndrome Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Short Bowel Syndrome Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Short Bowel Syndrome Market?

4. What is the competitive strategic window for opportunities in the Global Short Bowel Syndrome Market?

5. What are the technology trends and regulatory frameworks in the Global Short Bowel Syndrome Market?

6. What is the market share of the leading vendors in the Global Short Bowel Syndrome Market?

7. What modes and strategic moves are considered suitable for entering the Global Short Bowel Syndrome Market?

Market Dynamics

Drivers

• Increased prevalence of short bowel syndrome and awareness programs by non-profit organizations
• Rising efforts in the launch of effective treatments
• Awareness Programs by Non-Profit Organizations

Restraints

• Lack of approved treatment options
• Lethal adverse complications like colonic cancer, polyps along with common side effects associated with the medication

Opportunities

• Development of short bowel syndrome drugs is at a nascent stage
• Public-private partnerships are encouraging pharmaceutical companies to develop new orphan drugs for short bowel syndrome

Challenges

• Awareness among physicians

Companies Mentioned

• 9 Meters Biopharma, Inc.
• Adocia SAS
• Ardelyx Inc
• AstraZeneca PLC
• Emmaus Life Sciences, Inc.
• Johnson & Johnson Services, Inc.
• Merck KGaA
• Mylan N.V.
• Naia Pharmaceuticals, Inc.
• Nestle S.A.,
• Novartis International AG
• Nutrinia Ltd
• OPKO Health Inc.
• OxThera AB
• Pfizer Inc.
• PhaseBio Pharmaceuticals Inc.
• Sancilio & Company Inc
• Shire PLC
• Swedish Orphan Biovitrum AB
• Teva Pharmaceutical Industries Ltd
• VectivBio AG
• Zealand Pharma A/S

For more information about this report visit https://www.researchandmarkets.com/r/uenf0n

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900